161 related articles for article (PubMed ID: 8635863)
1. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab')2 in ovarian carcinoma patients.
Tibben JG; Boerman OC; Massuger LF; Schijf CP; Claessens RA; Corstens FH
Int J Cancer; 1996 May; 66(4):477-83. PubMed ID: 8635863
[TBL] [Abstract][Full Text] [Related]
2. Tumour targeting of the anti-ovarian carcinoma x anti-CD3/TCR bispesific monoclonal antibody OC/TR and its parental MOv18 antibody in experimental ovarian cancer.
Boerman OC; Tibben JG; Massuger LF; Claessens RA; Corstens FH
Anticancer Res; 1995; 15(5B):2169-74. PubMed ID: 8572619
[TBL] [Abstract][Full Text] [Related]
3. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
[TBL] [Abstract][Full Text] [Related]
4. Purification of bispecific F(ab')2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer.
Warnaar SO; De Paus V; Lardenoije R; Machielse BN; De Graaf J; Bregonje M; Van Haarlem H
Hybridoma; 1994 Dec; 13(6):519-26. PubMed ID: 7737675
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody.
Negri DR; Tosi E; Valota O; Ferrini S; Cambiaggi A; Sforzini S; Silvani A; Ruffini PA; Colnaghi MI; Canevari S
Br J Cancer; 1995 Oct; 72(4):928-33. PubMed ID: 7547242
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2.
Kroesen BJ; Buter J; Sleijfer DT; Janssen RA; van der Graaf WT; The TH; de Leij L; Mulder NH
Br J Cancer; 1994 Oct; 70(4):652-61. PubMed ID: 7917912
[TBL] [Abstract][Full Text] [Related]
7. Bispecific monoclonal antibodies for intravenous treatment of carcinoma patients: immunobiologic aspects.
Kroesen BJ; Janssen RA; Buter J; Nieken J; Sleijfer DT; Mulder NH; De Leij L
J Hematother; 1995 Oct; 4(5):409-14. PubMed ID: 8581377
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
9. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
11. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody.
Canevari S; Stoter G; Arienti F; Bolis G; Colnaghi MI; Di Re EM; Eggermont AM; Goey SH; Gratama JW; Lamers CH
J Natl Cancer Inst; 1995 Oct; 87(19):1463-9. PubMed ID: 7674333
[TBL] [Abstract][Full Text] [Related]
12. CD3 directed bispecific antibodies induce increased lymphocyte-endothelial cell interactions in vitro.
Molema G; Tervaert JW; Kroesen BJ; Helfrich W; Meijer DK; de Leij LF
Br J Cancer; 2000 Jan; 82(2):472-9. PubMed ID: 10646907
[TBL] [Abstract][Full Text] [Related]
13. Cytokine release in an ovarian carcinoma patient following intravenous administration of bispecific antibody OC/TR F(ab')2.
Tibben JG; Boerman OC; Claessens RA; Corstens FH; van Deuren M; de Mulder PH; van der Meer JW; Keijser KG; Massuger LF
J Natl Cancer Inst; 1993 Jun; 85(12):1003-4. PubMed ID: 8496973
[No Abstract] [Full Text] [Related]
14. Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomas.
Chatal JF; Saccavini JC; Gestin JF; Thédrez P; Curtet C; Kremer M; Guerreau D; Nolibé D; Fumoleau P; Guillard Y
Cancer Res; 1989 Jun; 49(11):3087-94. PubMed ID: 2720667
[TBL] [Abstract][Full Text] [Related]
15. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody.
Lamers CH; Bolhuis RL; Warnaar SO; Stoter G; Gratama JW
Int J Cancer; 1997 Oct; 73(2):211-9. PubMed ID: 9335445
[TBL] [Abstract][Full Text] [Related]
16. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
[TBL] [Abstract][Full Text] [Related]
17. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
[TBL] [Abstract][Full Text] [Related]
18. OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release.
Woodle ES; Thistlethwaite JR; Ghobrial IA; Jolliffe LK; Stuart FP; Bluestone JA
Transplantation; 1991 Aug; 52(2):354-60. PubMed ID: 1908148
[TBL] [Abstract][Full Text] [Related]
19. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
[TBL] [Abstract][Full Text] [Related]
20. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
